Class summary at a glance.

Every drug in the Microtubule Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 6tracked in Part D
CY24 Part D spend: $8.3Mcombined across class
Total Rx claims: 12K6K unique beneficiaries
Generic mfrs (active): 32across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Tirbanibulin

Brand: Klisyri · 4K Part D claims (CY24) · 3K beneficiaries · First FDA approval: 2020-12-14

Brand-only (no generics) 8 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $5.5M

Class share

66%

of class CY24 spend

View profile →

Docetaxel

Brand: BEIZRAY · 4K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 2010-10-21

11 generic mfrs Discontinued

Low NADAC—

→

Avg plan cost—

Part D spend $1.9M

Class share

23%

of class CY24 spend

View profile →

Eribulin

Brand: Halaven · 95 Part D claims (CY24) · 14 beneficiaries · First FDA approval: 2010-11-15

8 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend $614445

Class share

of class CY24 spend

View profile →

Paclitaxel

Brand: ABRAXANE · 3K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 2004-03-01

13 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend $304781

Class share

of class CY24 spend

View profile →

Paclitaxel (Aibumin-Bound)

Brand: Paclitaxel · — Part D claims (CY24) · First FDA approval: 2025-05-15

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Paclitaxel Protein-Bound Particles

— Part D claims (CY24) · First FDA approval: 2025-04-15

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.